FOLH1 and neoplasm: A very recent phase 1 study of a PSMA-specific armoured CAR T-cell therapy, engineered to express a dominant negative transforming growth factor-beta (TGF-β) to evade immunosuppression in the tumour microenvironment, demonstrated clinical activity in advanced castration-resistant prostate cancer [93].